Physician profile
Jonathan D Weaver
NPI 1851318331
$2,197.38
in general payments reported to CMS, 2019-2025
29 companies · $919 in 2025
The $919 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $440 · 2021: $190 · 2022: $92.77 · 2023: $90.45 · 2024: $259 · 2025: $919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $432.69 | 2020-2025 | |
| Pfizer INC. | $292.75 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $186.28 | 2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $147.63 | 2020-2025 | Mounjaro, Zepbound, Kisunla |
| Amgen INC. | $131.07 | 2021-2025 | Evenity, Prolia, Repatha |
| Bausch Health US, LLC | $115.85 | 2019-2025 | Wellbutrin, Aplenzin |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.61 | 2019-2025 | Xifaxan |
| Sumitomo Pharma America, INC. | $84.97 | 2025 | Gemtesa |
| Eisai INC. | $77.47 | 2020-2025 | |
| Novo Nordisk INC | $56.72 | 2025 | Wegovy, Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $55.85 | 2019-2021 | |
| Ibsa Pharma INC. | $52.86 | 2025 | Tirosint, Licart, Flector |
| Biohaven Pharmaceutical Holding Company Ltd. | $49.11 | 2022 | |
| Gilead Sciences, INC. | $43.96 | 2025 | |
| Exact Sciences Corporation | $36.25 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $33.43 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $30.48 | 2019-2020 | |
| Cleerly, INC. | $30.44 | 2025 | Cleerly Labs |
| Glaxosmithkline, LLC. | $30.28 | 2023 | Arexvy, Shingrix |
| Teva Pharmaceuticals USA, INC. | $27.24 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $26.42 | 2021 | |
| Viiv Healthcare Company | $25.02 | 2025 | Apretude |
| Alnylam Pharmaceuticals INC. | $24.50 | 2025 | Amvuttra |
| Allergan, INC. | $23.28 | 2020 | |
| Merck Sharp & Dohme LLC | $20.32 | 2021 | |
| Axsome Therapeutics, INC. | $20.23 | 2023 | Auvelity |
| Endo Pharmaceuticals INC. | $19.95 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.26 | 2019 | |
| Alfasigma USA, INC. | $14.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.